European Union antitrust regulators are reportedly leaning towards not soliciting feedback on the proposed remedies by Deutsche Boerse’s energy exchange unit, EEX, to secure approval for its acquisition of Nasdaq’s commodities clearing business. This move, as indicated by sources familiar with the matter, suggests a potentially smoother path for the deal’s approval.
The transaction, which has been under the scrutiny of the European Commission, the EU’s executive arm responsible for enforcing competition laws, is part of EEX’s strategy to expand its footprint in the energy clearing sector. The acquisition aims to integrate Nasdaq’s commodities clearing business, a key player in the market, under EEX’s umbrella, thereby enhancing its offerings and competitive edge in the industry.
Related: EEX Offers Remedies to Address EU Antitrust Concerns Over Nasdaq Deal
Typically, the European Commission seeks input from rivals and customers before making a final decision on such deals, especially when the parties involved propose remedies to address competition concerns. However, in this case, the decision to potentially bypass this step could indicate the Commission’s satisfaction with the remedies proposed by EEX, or a determination that the acquisition does not pose significant competition issues.
While the exact details of the proposed remedies have not been disclosed, the move by EU regulators not to seek further feedback could expedite the approval process, allowing EEX and Nasdaq to proceed with their plans without additional hurdles.
Featured News
AI Regulation and Human Rights: Building Trust through Multi-Stakeholder Collaboration
Jun 3, 2024 by
CPI
FBI Raids Corporate Landlord in Major Rent Price-Fixing Probe
Jun 3, 2024 by
CPI
American Airlines Seeks New Arrangement with JetBlue Pending Court Ruling Reversal
Jun 3, 2024 by
CPI
EU Regulators May Proceed Without Seeking Feedback on EEX-Nasdaq Remedies
Jun 3, 2024 by
CPI
Paramount-Skydance Deal Reaches Agreement on Merger Terms
Jun 3, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 31, 2024 by
CPI
AI and Antitrust Considerations in U.S. Health Care
May 31, 2024 by
CPI
Uncertainty in the Bottom Line: New Antitrust Scrutiny and Enforcement in Private Equity Transactions
May 31, 2024 by
CPI
Effecting M&A Diligence When Competitors Are Involved
May 31, 2024 by
CPI
AI, Pharmaceutical Sector, and EU Competition Law and Policy: What Does the Future Look Like?
May 31, 2024 by
CPI